Zogenix Inc. (ZGNX) and Arena Pharmaceuticals, Inc. (ARNA) Helped This Healthcare-Focused Fund Earn Double-Digit Returns
It's no secret that hedge funds have been underperforming the market by quite a wide margin in the last couple of years.
Founded in 2003, Great Point Partners is a private equity firm based in Greenwich, Connecticut. The firm specializes in investments in pharmaceutical infrastructure services, healthcare IT-enabled services, medical devices, and broader healthcare sectors. Great Point Partners focuses on opportunities in the United States, Canada, and Western Europe.
Dr. Jeffrey R. Jay has over 30 years of experience in private equity. Before founding Great Point Partners in 2003, he served for 11 years as a General Partner and head of the healthcare group at J.H. Whitney & Co., an investment firm managing over $6 billion in private equity, subordinated debt, and hedge funds. Dr. Jay has led numerous private equity investments and has served as chairman or board member for various companies, including AdvancePCS (ADVP), Axiom, Biotronic NeuroNetwork, Clinical Supplies Management, Concentra Managed Care (CCMC), Cytovance Biologics, Eon Labs (ELAB, acquired by Novartis), Equian, MaSTherCell, MLM, iXCells, Softbox Systems, SteriPack, Symbion (SYMB), U.S. Bioservices, Valenz, Velentium, and VetnCare. He earned his B.A. magna cum laude and his M.D. with honors from the six-year B.A./M.D. program at Boston University School of Medicine, and an M.B.A. from Harvard Business School. Dr. Jay is a member of the Dean’s Board of Advisors at Boston University School of Medicine and the Harvard Business School Health Care Advisory Board.
David Kroin is the founder of Deep Track Capital, an asset management firm dedicated to investing in human progress. Prior to this, he co-founded Great Point Partners. Mr. Kroin holds a B.S. in Actuarial Mathematics from the University of Michigan and serves on the Leadership Council for the university's Life Sciences Institute.
Great Point Partners is a hedge fund managing discretionary assets totaling $1,988,112,264, as reported in its Form ADV on April 2024. Serving 20 clients, their latest 13F filing for Q1 2024 disclosed $641,637,881 in managed 13F securities, with a top 10 holdings concentration of 51.56%. Neurogene Inc. represents Great Point Partners' largest holding, with 1,004,291 shares held.
